Results 111 to 120 of about 5,574 (244)

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]

, 2014
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R, Ambrósio, C, André, R, Araújo, F, Barcelos, F, Bernardes, M, Bogas, M, Canhão, H, Castelão, W, Coelho, PC, Cordeiro, I, Costa, L, Cunha, I, Duarte, C, Faustino, A, Fernandes, S, Fonseca, JE, Garcês, S, Gonçalves, J, Las, V, Leitão, R, Malcata, A, Maurício, L, Meirinhos, T, Melo-Gomes, JA, Miguel, C, Miranda, LC, Monteiro, P, Neto, A, Pereira da Silva, JA, Pimenta, S, Pimentel-Santos, FM, Pimentão, JB, Ramiro, Sofia, Ramos, JC, Roxo, Ana, Santos, H, Sepriano, A, Silva, C, Silva, M, Tavares, V, Teixeira, F   +41 more
core  

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.
Ailsa Hart, Seyedehsan Navabi, Geert D'Haens, Katsuyoshi Matsuoka, María Dolores Martín‐Arranz, Raja Atreya, Karen Hamrick Samaan, Endip Dhesi, Isabel Redondo, Baojin Zhu, Jerome Paulissen, Liliana Zaremba‐Pechmann, Simin Baygani, Jimmy Limdi, David Laharie, Silvio Danese   +15 more
wiley   +1 more source

Review on lipegfilgrastim

International Journal of Nanomedicine, 2015
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of ...
Gasparic M, Leyman S
doaj  

Limited Options to Manage Specialty Drug Spending [PDF]

, 2012
Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core  

Fractal Growth on the Surface of a Planet and in Orbit around it [PDF]

, 2014
Fractals are defined as geometric shapes that exhibit symmetry of scale. This simply implies that fractal is a shape that it would still look the same even if somebody could zoom in on one of its parts an infinite number of times.
Alexiou, Athanasios, Gkigkitzis, Ioannis, Haranas, Ioannis   +2 more
core   +3 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Evolution of Biosimilar Medicines on the Romanian Pharmaceutical Market

Acta Pharmaceutica Hungarica, 2021
Emese Sipos, Emőke Rédai, Ibolya Fülöp   +2 more
openaire   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development

Biologics: Targets & Therapy
Ranjit Ranbhor,1 Priyanka Kulkarni2 1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA; 2Feliciano School of Business, Montclair State University, Montclair, NJ, USACorrespondence: Ranjit Ranbhor, Business ...
Ranbhor R, Kulkarni P
doaj